Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159357 | 0.82 | BCHE (0.38) | MAPTBCHEALDH1A1BUB1GPR119 | |
| SCHEMBL2959354 | 0.82 | BCHE (0.38) | MAPTBCHEALDH1A1BUB1GPR119 | |
| SCHEMBL3739164 | 0.81 | BCHE (0.36) | MAPTBCHEALDH1A1BUB1GPR119 | |
| SCHEMBL20141107 | 0.81 | BCHE (0.37) | ELANEBCHEBUB1GPR119MEN1 | |
| SCHEMBL22952412 | 0.81 | BCHE (0.37) | MAPTKDM4EBCHEALDH1A1BUB1 | |
| SCHEMBL306662 | 0.81 | HSP90AA1 (0.39) | BCHEBUB1GPR119MEN1KMT2A | |
| SCHEMBL17377610 | 0.81 | BCHE (0.37) | BCHEBUB1GPR119MEN1KMT2A | |
| SCHEMBL12128384 | 0.79 | PLAU (0.51) | NOS1PLAUELANEF2KLKB1 | |
| SCHEMBL18068142 | 0.79 | BCHE (0.36) | PLAUELANEF2KLKB1SIRT5 | |
| SCHEMBL17633162 | 0.79 | CYP4F2 (0.39) | MAPTBCHEHPGDBUB1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134022-B | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118510761-A | Crystalline forms of ATR inhibitors | 上海德琪医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118239963-A | Compounds as eIF4E inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116507337-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4199919-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| US-5958918-A | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. | 1999-09-28 | — | — | US | disclosed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | NOS1 2321/4885PLAU 289/4885ELANE 524/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | NOS1 3565/4885PLAU 1105/4885ELANE 1852/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | NOS1 529/4885PLAU 3208/4885ELANE 3280/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | NOS1 267/4885PLAU 2709/4885ELANE 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.